Purpose.
Although interferon (IFN) is commonly used for the treatment of chronic hepatitis C virus (HCV) infection, eradication of the virus occurs in only a small proportion of patients with genotype 1b and a high virus titer. Modified IFN therapies have been tried, with only limited benefit. Recently, the administration of IFN-beta twice per day has been reported to be more effective than the usual once-daily administration regimen. The aim of this study was to evaluate whether twice-daily IFN results in a sustained response in patients with chronic HCV infection with genotype 1b and a high virus titer. Methods. Twenty patients with genotype 1b and high HCV RNA level (more than 1 MEq/ml by branched DNA probe assay) were randomly assigned to receive either twice-daily 3 MU of IFN beta (group A) or once-daily 6 MU of IFN-beta (group B) for 4 weeks. All patients received a further daily dose of 6 MU IFN-beta for 12 weeks, followed by IFN-alfa three times a week for 16 weeks. Results. Although a rapid fall in HCV RNA levels was noted in group A, a sustained response was observed in only one of nine patients in this group, and none of group B. Adverse effects of IFN were more frequent and pronounced in group A than in group B. Conclusions. We conclude that further modification, which combines the early strong anti-viral effects of the twice-daily regimen with long-term sustained response, is necessary for effective therapy of HCV patients with genotype 1b and high HCV RNA levels.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: June 22, 2000 / Accepted: November 10, 2000
Rights and permissions
About this article
Cite this article
Suzuki, F., Chayama, K., Tsubota, A. et al. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol 36, 242–247 (2001). https://doi.org/10.1007/s005350170110
Issue Date:
DOI: https://doi.org/10.1007/s005350170110